Antineoplastic Agents, Hormonal
"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
| Descriptor ID |
D018931
|
| MeSH Number(s) |
D27.505.954.248.169
|
| Concept/Terms |
Antineoplastic Agents, Hormonal- Antineoplastic Agents, Hormonal
- Hormonal Agents, Antineoplastic
- Hormonal Antineoplastic Agents
- Hormonal Antineoplastics
- Antineoplastic Hormonal Drugs
- Drugs, Antineoplastic Hormonal
- Hormonal Drugs, Antineoplastic
- Hormonal Antineoplastic Drugs
- Antineoplastics, Hormonal
- Antineoplastic Hormonal Agents
- Agents, Antineoplastic Hormonal
- Antineoplastic Drugs, Hormonal
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".
This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 5 | 2 | 7 |
| 1997 | 4 | 2 | 6 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 5 | 0 | 5 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 8 | 3 | 11 |
| 2004 | 6 | 5 | 11 |
| 2005 | 11 | 4 | 15 |
| 2006 | 5 | 1 | 6 |
| 2007 | 3 | 4 | 7 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 0 | 3 |
| 2011 | 8 | 5 | 13 |
| 2012 | 3 | 4 | 7 |
| 2013 | 3 | 3 | 6 |
| 2014 | 4 | 1 | 5 |
| 2015 | 5 | 3 | 8 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 4 | 6 |
| 2018 | 2 | 4 | 6 |
| 2019 | 2 | 5 | 7 |
| 2020 | 1 | 3 | 4 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.
-
The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(40):3351-3354.
-
Neoadjuvant Radiotherapy and Endocrine Therapy for Oestrogen Receptor Positive Breast Cancers: The Neo-RT Feasibility Study. Clin Oncol (R Coll Radiol). 2025 Jan; 37:103669.
-
Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study. Gynecol Oncol. 2024 Dec; 191:143-149.
-
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Oct 01; 10(10):1379-1389.
-
Exogenous steroid replacement in a pediatric patient with adrenocortical carcinoma receiving mitotane. Pediatr Blood Cancer. 2024 Aug; 71(8):e31072.
-
The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers. Br J Cancer. 2024 May; 130(11):1875-1884.
-
Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response. Nat Genet. 2024 Apr; 56(4):637-651.
-
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1111-1120.
-
Geographic Variations and the Associated Factors in Adherence to and Persistence with Adjuvant Hormonal Therapy for the Privately Insured women Aged 18-64 with Breast Cancer in Texas. Curr Oncol. 2023 03 29; 30(4):3800-3816.
-
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375.